Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
- Saturday, October 2, 2021, 7:10
- PR Newswire
- Add a comment
THOUSAND OAKS, Calif. and TOKYO, Oct. 2, 2021 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were presented at the European Academy of Dermatology and Venereology 30th Virtual Congress on…
About the Author
admin has written 20720 stories on this site.